Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

PartnershipIBI355Positive

AI Analysis

Summary

Innovent Biologics and Spero Therapeutics announced an exclusive license agreement for IBI355 (SP001), a Phase 2-ready third-generation anti-CD40L antibody. The partnership expands the development and commercialization potential of the candidate.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Exclusive license agreement announced

Importance:7/10

Sentiment:

0.60

licensingpartnershipimmunologyanti-CD40LPhase 2

Related Companies

$IVBXF

Read the original article

Published by yahoo_finance on July 14, 2026 10:00 AM

Read Original